<DOC>
	<DOCNO>NCT01518855</DOCNO>
	<brief_summary>The primary objective study investigate incremental cost effectiveness Nifedipine CR Amlodipine combination therapy Valsartan treatment essential hypertensive patient . To investigate incremental cost effectiveness , primary variable mean treatment cost achievement rate target blood pressure level end double-blind treatment period .</brief_summary>
	<brief_title>Controlled Release Nifedipine Valsartan Combination Therapy Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Untreated patient patient previous treatment antihypertensive agent whose blood pressure sit position time entry ( Visit 1 ) : SBP &gt; /=160mmHg DBP &gt; /=100mmHg untreated patient ( SBP Systolic blood pressure , DBP Diastolic blood pressure ) SBP &gt; /=150mmHg DBP &gt; /=95mmHg patient previous treatment antihypertensive agent Patients whose blood pressure either day Visit 1 2 : SBP &gt; 200mmHg DBP &gt; 120mmHg . Patients secondary hypertension hypertensive emergency malignant hypertension . Patients history cardiovascular cerebrovascular ischemic event ( stroke , transient ischemic attack , myocardial infarction unstable angina ) within six month prior study . Patients history intracranial subarachnoid hemorrhage within six month prior study . Patients uncontrolled diabetes ( HbA1c &gt; /=8 % ) Patients bradycardia tachycardia ( &lt; 50 bpm , &gt; /=100 bpm ) , arrhythmia atrioventricular block ( second third degree ) , sinoatrial block atrial fibrillation .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>